Glaucoma Trial, Recruiting NCT06682962 Sponsor: Okuvision GmbH Condition: Glaucoma
Back to Glaucoma

Glaucoma Trial, Recruiting

NCT06682962
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to take part and can sign a consent form before the study begins
  • You are 40 years old or older
  • You have been diagnosed with one of these types of glaucoma in the eye being studied: primary open-angle glaucoma, pseudoexfoliation glaucoma, pigment dispersion glaucoma, or normal tension glaucoma
  • Your glaucoma is getting worse in the study eye, with vision loss progressing at a certain measurable rate, and your overall vision loss falls within a specific moderate range (confirm with trial site for exact measurements)
  • You have at least some usable vision remaining in the study eye (not severely impaired)
  • You are able to learn how to use a home stimulation device after thorough training
  • You are able to understand what taking part in the study involves and what it means for you personally
  • You are able to give informed consent to participate
  • If both eyes could qualify, the trial team will follow a set process to decide which eye is used as the study eye (confirm with trial site)
  • If you are a woman who could become pregnant, you must have a negative pregnancy test at the start of the screening process
  • If you are a woman who could become pregnant, you must agree to either abstain from sex or use highly effective contraception throughout the study

Who may not be able to join:

  • You have abnormal new blood vessel growth of any kind in the study eye
  • You have had a blood vessel blockage (arterial or venous) in the study eye
  • You have had surgery inside the study eye within the last 3 months before screening
  • You currently have an active eye inflammation in either eye
  • You have diabetic damage to the retina in the study eye
  • You have had a detached retina in the study eye
  • You have a form of age-related macular degeneration (dry type) that is affecting your vision in the study eye
  • You have the wet (exudative) form of age-related macular degeneration in the study eye
  • You have swelling of the central part of the retina (macular edema) in the study eye, for any reason
  • You have other significant retinal conditions in the study eye
  • You have a condition affecting the clear front surface of the eye (cornea) that limits your vision in the study eye
  • You have any condition other than glaucoma that affects the central area of your vision in the study eye
  • You have planned cataract surgery or other eye surgery on the study eye during the trial period (laser trabeculoplasty may be an exception — confirm with trial site)
  • You have an active medical implant (such as a pacemaker) (confirm with trial site)
  • You have a serious or hard-to-manage general health condition that, in the doctor's opinion, could interfere with your participation
  • You are in poor general health, as judged by the study doctor
  • You have a mental health condition or dementia that, in the doctor's opinion, would make it difficult to understand and follow the study procedures
  • You are currently taking part in another clinical trial, or recently finished one whose effects may still be active (within the last 30 days)
  • You are currently breastfeeding
  • You are unable to give consent yourself
  • You have previously taken part in the TES-GPS study
  • You have an allergy or sensitivity to silver, which is relevant to the device used in this study (OkuStim 2)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Katrin Lorenz, Prof., Augenklinik und Poliklinik der Universitätsmedizin Mainz, Johannes Gutenberg-Universität Mainz

Phone: +49 6131 174069

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Okuvision GmbH
Registry
ClinicalTrials.gov
Start date
2 April 2025
Est. completion
1 June 2028

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Difference in Humphrey visual field examination between the TES-treated group and the sham-treated group

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov